TRANSFORMATIVE CANCER THERAPIES. TARGETED IMPACT.
Immunotherapy represents one of the greatest advances for people living with cancer, but off-target effects remain a challenge in the clinical setting.
Our technology is designed to unleash validated and proven proinflammatory mechanisms on tumors while preventing unwanted side effects on non-target tissue. We create systemically delivered targeted therapies that address the limitations of immuno-oncology.
Werewolf Therapeutics is a highly innovative company striving to redefine the cancer treatment landscape with potential best-in-class therapies.
Our technology is designed to unleash validated and proven proinflammatory mechanisms on tumors while preventing unwanted side effects on non-target tissue. We create systemically delivered targeted therapies that address the limitations of immuno-oncology.
Werewolf Therapeutics is a highly innovative company striving to redefine the cancer treatment landscape with potential best-in-class therapies.
OUR GOAL IS TO TRANSFORM THE LIVES OF CANCER PATIENTS
INNOVATIVE CANCER THERAPIES DIFFERENTIATED BY DESIGN
We are advancing a novel class of cancer biotherapeutics designed to enhance the body’s immune response to cancer.
These conditionally activated proinflammatory immune modulators, called INDUKINE™ molecules, are systemically administered in an inactive form and are selectively activated to deliver full biological potency of cytokines upon entering the tumor microenvironment.
Our team of experienced scientists invented our proprietary PREDATOR™ protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients.


What’s in a name?
The company name is a powerful analogy to our scientific approach. A werewolf is a creature that goes unnoticed in day-to-day life but transforms into a dangerous predator under specific conditions. That is exactly what the medicines that we are developing do.
Our molecules are delivered systemically and remain inactive in the body as they are drawn to the tumor microenvironment, at which point they stimulate a powerful immune response and unleash an attack on cancer cells.
Our molecules are delivered systemically and remain inactive in the body as they are drawn to the tumor microenvironment, at which point they stimulate a powerful immune response and unleash an attack on cancer cells.
Press Releases
May 10, 2022
Werewolf Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights
Entered exclusive global license and collaboration agreement with Jazz Pharmaceuticals to develop and commercialize WTX-613
Read More
April 8, 2022
Werewolf Therapeutics Presents Promising Preclinical Data on its Two Lead INDUKINE™ Molecules at AACR 2022 Annual Meeting
WTX-124 demonstrated high tumor selectivity and generated significant anti-tumor activity in a CD8+ T cell-dependent
Read More
April 7, 2022
Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE™ Molecule
Werewolf to receive $15 million upfront payment, with potential for up to $1.26 billion in
Read More
Join Our Team
Are you someone who makes things happen? Do you want to work at a company that embraces the same ideals? We’re looking for vibrant, creative, forward-thinking people to join our team. Click the link below and let us know that you’re interested. We’d love to talk to you.
Research Scientist I/II, Translational Research
This individual will work closely with the rest of the Translational team to develop and execute project plans and timelines,
Full Job Description
Research Scientist III, Protein Biochemistry
The successful candidate will be a creative scientist, with strong problem-solving skills and demonstrated experience in protein biochemistry and antibody/therapeutic
Full Job Description
Staff/Senior Accountant
We are currently seeking a Staff/Senior Accountant to join our rapidly growing team.
Full Job Description